Jingxin Pharmaceutical to re-elect board, update governance for efficiency

Zhejiang Jingxin Pharmaceutical (SZSE:002020) announced on September 24, 2025, that its eighth board of directors will undergo re-election for the ninth board. The ninth board will comprise nine directors: six non-independent directors (one employee representative) and three independent directors. The independent director candidates have obtained necessary qualification certificates, which will be submitted to the Shenzhen Stock Exchange for review. The re-election will use a cumulative voting system at the 2025 first extraordinary general meeting.

Concurrently, the company is revising its Articles of Association to align with updated regulations and internal restructuring. Key changes include renaming "shareholder general meeting" to "shareholders' meeting," eliminating the supervisory board by transferring its functions to the board's audit committee, and incorporating new provisions for independent directors and internal audit. Jingxin Pharmaceutical also updated its management policies for raised funds, external guarantees, and entrusted wealth management, reflecting stricter controls and compliance with regulatory guidelines. These revisions aim to streamline governance and enhance risk management.